Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Takecab Faces 2nd “Huge-Seller” Price Slash, All GLP-1 Injectables to Get Cut Too on Market Expansion
January 18, 2022
- Bayer’s CKD Drug Finerenone Up for PAFSC Review on Jan. 28
January 17, 2022
- FY2022 Medical Fee Reform Plans OK’ed by Chuikyo, No Mention of Formulary
January 17, 2022
- MHLW Presents Preventive Steps after SaMD Deferred Coverage Case: Chuikyo
January 17, 2022
- Japan Cuts Review Fees for Fertility Treatments by Half
January 14, 2022
- Pfizer’s Comirnaty Up for PAFSC Review for Ages 5-11 on Jan. 20; Actemra to Add COVID-19 Use
January 14, 2022
- MHLW to Promote Use of Generics, Biosimilars through FY2022 Medical Fee Schedule Revision: Chuikyo
January 13, 2022
- AMED to Set Up SCARDA in March to Spearhead Vaccine Development: President
January 12, 2022
- Govt to Move Up Booster Schedule for Workplace Program Too: Minister
January 12, 2022
- PM Kishida Vows to Hasten COVID-19 Vaccinations for under Age 12
January 12, 2022
- MHLW to Revise Laws to Allow Doctors to Issue Electronic Scripts
January 11, 2022
- MHLW Eyes Evaluation Indices and Guidelines to Fuel Rollout of SaMD and Cell & Gene Therapies: Official
January 11, 2022
- Govt to Submit PMD Law Amendment Bill in Ordinary Diet Session to Introduce Emergency Approval
January 7, 2022
- Rewarding Innovation Was the Primary Goal in 2022 Reform Debate: MHLW Official
January 7, 2022
- MHLW to Reshuffle Organization by Summer to Further Support Drug Development; Economic Affairs Division to Be Renamed
January 7, 2022
- MHLW’s COVID-19 Guide Adds MSD’s Molnupiravir
January 6, 2022
- Japan’s Drug Production Down 1.9% to 9.3 Trillion Yen in 2020: MHLW
January 6, 2022
- Japan Govt to End Observational Avigan Study for COVID-19
January 5, 2022
- MHLW Finalizes Paper on Emergency Approval System, Set to Submit Bill Next Year
December 28, 2021
- 50 Million Yen Earmarked to Support API Stockpiles to Ensure Stable Supplies: MHLW FY2022 Budget
December 28, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…